These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2230886)

  • 1. Monoclonal antibodies and radioimmunoconjugates: keeping feasibility at center stage.
    Knapp RC; Lau CC
    J Clin Oncol; 1990 Dec; 8(12):1938-40. PubMed ID: 2230886
    [No Abstract]   [Full Text] [Related]  

  • 2. The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates.
    Hopkins K; Papanastassiou V; Kemshead JT
    Recent Results Cancer Res; 1996; 141():159-75. PubMed ID: 8722426
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.
    Tempero M; Leichner P; Baranowska-Kortylewicz J; Harrison K; Augustine S; Schlom J; Anderson J; Wisecarver J; Colcher D
    Clin Cancer Res; 2000 Aug; 6(8):3095-102. PubMed ID: 10955789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer.
    Stewart JS; Hird V; Snook D; Dhokia B; Sivolapenko G; Hooker G; Papadimitriou JT; Rowlinson G; Sullivan M; Lambert HE
    J Clin Oncol; 1990 Dec; 8(12):1941-50. PubMed ID: 2230887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How and why does radioimmunotherapy work?
    Macklis RM
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1269-71. PubMed ID: 15275708
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
    Wong JY; Chu DZ; Williams LE; Liu A; Zhan J; Yamauchi DM; Wilczynski S; Wu AM; Yazaki PJ; Shively JE; Leong L; Raubitschek AA
    Cancer Biother Radiopharm; 2006 Apr; 21(2):88-100. PubMed ID: 16706629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies and immunoconjugates for cancer treatment.
    Baldwin RW; Byers VS; Pimm MV
    Cancer Chemother Biol Response Modif; 1988; 10():397-415. PubMed ID: 3079393
    [No Abstract]   [Full Text] [Related]  

  • 8. Monoclonal antibodies. Targeted treatment.
    Mayo Clin Health Lett; 2003 Mar; 21(3):1-3. PubMed ID: 12703461
    [No Abstract]   [Full Text] [Related]  

  • 9. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
    J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody conjugates for the treatment of cancer.
    Pietersz GA; McKenzie IF
    Immunol Rev; 1992 Oct; 129():57-80. PubMed ID: 1464422
    [No Abstract]   [Full Text] [Related]  

  • 12. Underestimation of absorbed dose to kidney.
    Postema EJ; Buijs WC; Boerman OC; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1707-8. PubMed ID: 14530491
    [No Abstract]   [Full Text] [Related]  

  • 13. [Radioimmunotherapy for B-cell lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2006 Jun; 47(6):463-70. PubMed ID: 16862974
    [No Abstract]   [Full Text] [Related]  

  • 14. Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma.
    Shen S; Forero A; Meredith RF; LoBuglio AF
    Cancer Biother Radiopharm; 2011 Feb; 26(1):127-33. PubMed ID: 21355784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically engineered monoclonal antibodies armed with radionuclides.
    Waldmann TA
    Year Immunol; 1993; 7():205-12. PubMed ID: 8103951
    [No Abstract]   [Full Text] [Related]  

  • 16. Recent therapeutic advances in hematological malignancies: the role of targeted therapies in lymphoma.
    Schmitz N
    Ann Oncol; 2008 Jul; 19 Suppl 5():v63-7. PubMed ID: 18611903
    [No Abstract]   [Full Text] [Related]  

  • 17. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second generation of targeted drugs.
    Practitioner; 1987 Feb; 231(1424):137-8. PubMed ID: 3500468
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of trastuzumab.
    Vogel CL; Reddy JC; Reyno LM
    Cancer Res; 2005 Mar; 65(5):2044. PubMed ID: 15753405
    [No Abstract]   [Full Text] [Related]  

  • 20. Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma.
    Postema EJ; Frielink C; Oyen WJ; Raemaekers JM; Goldenberg DM; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):525-33. PubMed ID: 14503946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.